Adverse events160

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 160

Type	Event	Organ system	Group	Affected	At risk
other	Lymphadenopathy	Blood and lymphatic system disorders	Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase	0	36
other	Lymphadenopathy	Blood and lymphatic system disorders	Placebo - Placebo-Controlled Phase	2	35
other	Lymphadenopathy	Blood and lymphatic system disorders	Ritlecitinib 50 mg QD - Active Therapy Extension Phase	0	32
other	Lymphadenopathy	Blood and lymphatic system disorders	Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase	0	33
other	Lymphadenopathy	Blood and lymphatic system disorders	Ritlecitinib 50 mg QD: Extension Phase	0	45
other	Tinnitus	Ear and labyrinth disorders	Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase	2	36
other	Tinnitus	Ear and labyrinth disorders	Placebo - Placebo-Controlled Phase	0	35
other	Tinnitus	Ear and labyrinth disorders	Ritlecitinib 50 mg QD - Active Therapy Extension Phase	0	32
other	Tinnitus	Ear and labyrinth disorders	Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase	0	33
other	Tinnitus	Ear and labyrinth disorders	Ritlecitinib 50 mg QD: Extension Phase	0	45
other	Diarrhoea	Gastrointestinal disorders	Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase	3	36
other	Diarrhoea	Gastrointestinal disorders	Placebo - Placebo-Controlled Phase	0	35
other	Diarrhoea	Gastrointestinal disorders	Ritlecitinib 50 mg QD - Active Therapy Extension Phase	0	32
other	Diarrhoea	Gastrointestinal disorders	Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase	0	33
other	Diarrhoea	Gastrointestinal disorders	Ritlecitinib 50 mg QD: Extension Phase	1	45
other	Nausea	Gastrointestinal disorders	Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase	1	36
other	Nausea	Gastrointestinal disorders	Placebo - Placebo-Controlled Phase	3	35
other	Nausea	Gastrointestinal disorders	Ritlecitinib 50 mg QD - Active Therapy Extension Phase	0	32
other	Nausea	Gastrointestinal disorders	Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase	0	33
other	Nausea	Gastrointestinal disorders	Ritlecitinib 50 mg QD: Extension Phase	0	45

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04517864/events

API reference For AI assistants

Adverse events160

Sources 3

Read this list from software.